- The software-guided GlucoStabilizer (Medical Decision Network, LLC, licensed to Indiana University) can improve intrapartum glycemic control in pregestational or gestational diabetes treated with insulin infusion.
Why this matters
- Maintenance of maternal euglycemia during labor reduces risk for neonatal hypoglycemia, associated morbidities.
- GlucoStabilizer is a software-guided insulin dosing system that calculates needed intravenous (IV) insulin dose based on metabolic parameters, target glucose, individual response to insulin.
- Retrospective cohort study compared laboring patients with diabetes requiring insulin infusion (pregestational or gestational) dosed by standard insulin dosing chart from January 2012 to April 2016 (n=22) vs GlucoStabilizer during May 2016 to December 2017 (n=11) for ≥2 hours.
- Funding: None disclosed.
- Before IV insulin initiation, mean capillary blood glucose was 122.6 mg/dL for GlucoStabilizer and 131.9 mg/dL for standard insulin groups (P=not significant).
- After IV insulin initiation, mean glucose was 102.9 vs 121.7 mg/dL for GlucoStabilizer vs standard dosing, respectively (P=.02).
- Percentages achieving blood glucose 70-100 mg/dL predelivery were 81.8% vs 9.1%, respectively (P=.0001).
- Mean capillary blood glucose 1 hour before delivery was 92.5 vs 122 mg/dL, respectively (P<.05>
- No episodes of maternal hypoglycemia and no significant differences in neonatal outcomes.
- Small sample size.